India Patient Derived Xenografts/PDX Models Market (2025-2030)
The India Patient Derived Xenografts/PDX Models Market was valued at $4.1 Million in 2025 and projected to reach to $7 Million by 2030, representing a compound annual growth rate of 11.0%. India's PDX Models market is poised for sustained growth as the country strengthens its position in global oncology research.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
India Patient Derived Xenografts/PDX Models Market Trends and Insights
- India is emerging as a key player in the Asia Pacific PDX market, driven by increasing investments in oncology research and personalized medicine initiatives.
- The market in India reflects growing adoption of PDX models among research institutions and pharmaceutical companies seeking advanced preclinical testing platforms. The 11.0% compound annual growth rate (CAGR) through 2030 underscores India's commitment to advancing cancer research infrastructure and drug development capabilities.
- India's expanding biotechnology sector and government support for healthcare innovation are accelerating PDX model adoption.
- By 2030, India is expected to strengthen its position as a regional hub for translational research, with PDX models becoming integral to India's precision oncology ecosystem and clinical trial frameworks..
Key Market Statistics
- CAGR (2025-2030) 11.0% CAGR
- Market Size, 2025 ~USD 4.1 Million
- Forecast, 2030 ~USD 7 Million
- Country India
India Patient Derived Xenografts/PDX Models Market Overview
Market Valuation Growth :
India's PDX Models market is valued at $4.1 million in 2025, with a projected CAGR of 11% through 2030, reaching $7.0 million. This growth trajectory positions India as a significant contributor to the Asia Pacific PDX market expansion.
Oncology Research Investments :
Increasing government and private sector investments in oncology research are driving PDX model adoption across Indian research institutions. These initiatives support personalized medicine development and cancer drug discovery programs.
Personalized Medicine Adoption :
Indian pharmaceutical and biotech companies are increasingly leveraging PDX models for precision oncology applications. This shift reflects growing recognition of patient-derived models in improving drug efficacy and reducing development timelines.
Research Infrastructure Expansion :
Major research centers and contract research organizations (CROs) in India are establishing dedicated PDX facilities. This infrastructure development supports both domestic research needs and international collaborations in cancer therapeutics.
India Patient Derived Xenografts/PDX Models Market Dynamics
- The convergence of increased R&D investments, growing pharmaceutical sector capabilities, and rising demand for personalized medicine solutions creates favorable conditions for market expansion.
- Indian research institutions and CROs are increasingly adopting PDX models to enhance drug development efficiency and reduce time-to-market for cancer therapeutics. The market outlook is further supported by government initiatives promoting precision medicine and biotech innovation.
- As Indian companies establish international partnerships and expand their research capabilities, PDX model adoption is expected to accelerate.
- The projected growth from $4.1 million to $7.0 million by 2030 reflects India's emerging role as a key hub for advanced oncology research in the Asia Pacific region..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- India's PDX Models market is valued at $4.1 million in 2025 and is forecast to reach $7.0 million by 2030, representing an 11.0% CAGR.
- India is leveraging PDX models to advance personalized medicine and oncology research, positioning itself as a regional translational research hub.
- Government initiatives and biotechnology sector expansion in India are driving increased adoption of PDX platforms among research institutions and pharmaceutical companies.
- By 2030, India's PDX market growth will reflect strengthened infrastructure for precision oncology and enhanced drug development capabilities across the country.
Patient Derived Xenografts/PDX Models Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | ORTHOTOPIC IMPLANTATION (Implantation Method) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 12.5% from 2025 to 2030 |
| Largest Segment | PDX MODELS (Model Type & Service) |
| Market Size Base Year (Billions) | ~USD 0.37 (2025) |
| Revenue Forecast (Billions) | ~USD 0.66 (2030) |
| Segments Covered | Model Type & Service, Type, Implantation Method |
India Patient Derived Xenografts/PDX Models Market Report Segmentation
3 segment dimensions are covered across the global market.
By Model Type & Service
- Pdx Models
- Pdx Services
By Type
- Cryopreservation Services
- Model Characterization Services
- Model Creation & Expansion Services
- Mouse Model
- Other Pdx Services
- Rat Model
By Implantation Method
- Orthotopic Implantation
- Other Implantation Methods
- Subcutaneous Implantation
INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 1.05 | 1.16 | 1.29 | 1.44 | 1.59 | 1.75 | 1.93 | 2.13 | 10.5 |
| CROS & CDMOS | 0.68 | 0.75 | 0.83 | 0.92 | 1.01 | 1.11 | 1.22 | 1.34 | 10.1 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 2.18 | 2.44 | 2.73 | 3.07 | 3.42 | 3.81 | 4.24 | 4.7 | 11.5 |
| TOTAL | 3.9 | 4.35 | 4.85 | 5.42 | 6.03 | 6.67 | 7.39 | 8.17 | 11 |
Target Audience
- Pharmaceutical Companies : Indian and multinational pharma firms need India-specific PDX market data to assess adoption rates, identify partnership opportunities with research institutions, and plan oncology drug development investments in the country.
- Biotech & CRO Organizations : Contract research organizations and biotech companies operating in India require market insights to evaluate PDX service demand, benchmark capabilities against competitors, and identify growth opportunities in personalized medicine.
- Research Institutions : Academic medical centers and research organizations in India need market intelligence to justify PDX facility investments, understand funding trends, and position themselves within the growing oncology research ecosystem.
- Healthcare Investors : Venture capital and private equity firms investing in Indian healthcare need comprehensive PDX market data to evaluate investment opportunities, assess market potential, and identify high-growth companies in precision oncology.
- Government & Policy Bodies : Indian health ministry and research councils require market analysis to inform precision medicine policies, allocate research funding effectively, and develop strategies supporting the country's oncology research capabilities.
Key Companies in the India Patient Derived Xenografts/PDX Models Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CHARLES RIVER LABORATORIES | United States | Public Company | Research Models and Services,Discovery and Safety Assessment,Manufacturing Solutions, |
| THE JACKSON LABORATORY | United States | Foundation/Charitable Institution | Mouse breeding & colony management,Phenotyping, efficacy testing & study-ready induced models,Genetic research services & bioinformatics, |
| INOTIV | United States | Public Company | Research Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software, |
| JSR CORPORATION | Japan | Private Company | Digital Solutions (lithography, photoresists, CMP, display, 3D printing),Plastics (ABS, AES, AS, ASA resins),Life Sciences (diagnostics, reagents, bioprocess, drug discovery support), |
| GENOWAY | France | Public Company | Custom mouse models (KO/KI, humanized, immune checkpoint),Custom rat models (KO/KI, immunodeficient, reconstituted),Custom cell lines (KO/KI, reporter, inducible), |
| BIOCYTOGEN PHARMACEUTICALS CO., LTD. | China | Public Company | Gene-Editing Services,Pharmacological Efficacy and Toxicology Services,Model Animals, |
| CHAMPIONS ONCOLOGY, INC. | United States | Public Company | Tumorgraft-based translational oncology services,Personalized cancer care / patient-specific Tumorgraft programs,Lumin Bioinformatics and data-driven software, |
| PHARMARON | China | Public Company | Laboratory Services,Chemical and Formulation Process Development and Manufacturing Services (Small Molecule CDMO),Clinical Research Services, |
| SYNGENE INTERNATIONAL LIMITED | India | Public Company | Discovery services (chemistry and biology),Development services (preclinical, CMC, clinical development),Manufacturing (API and drug product, including biologics), |
| LABCORP | United States | Public Company | Routine and preventive diagnostics (chemistry, hematology, urinalysis, wellness),Specialty and esoteric testing (genetic, oncology, infectious disease, women’s health),Biopharma laboratory services and clinical trial testing, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Food and Feed Testing,Environmental Testing,Biopharma Testing and Services, |
CHARLES RIVER LABORATORIES
Charles River Laboratories is a public company founded in 1947 and headquartered in the United States. With 19,000 employees, it operates as a major provider of preclinical and clinical laboratory services.
THE JACKSON LABORATORY
The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States. The organization employs 2,100 staff members and focuses on genetic research and related scientific services.
INOTIV
INOTIV is a public company founded in 1974 and based in the United States. The company operates with 1,996 employees and provides research and development services.
JSR CORPORATION
JSR Corporation is a private company founded in 1948 and headquartered in Japan. With 7,997 employees, the company operates across multiple business segments.
GENOWAY
GENOWAY is a public company founded in 1999 and based in France. The organization employs 157 staff members and operates in the biotechnology sector.
BIOCYTOGEN PHARMACEUTICALS CO., LTD.
BIOCYTOGEN PHARMACEUTICALS CO., LTD. is a public company founded in 2008 and based in China. The company employs 1,443 staff members and operates in the pharmaceutical and biotechnology sectors.
CHAMPIONS ONCOLOGY, INC.
Champions Oncology, Inc. is a public company founded in 1985 and based in the United States. The company employs 214 staff members and operates in the oncology research and services sector.
PHARMARON
PHARMARON is a public company founded in 2004 and based in China. With 25,088 employees, the company provides drug discovery and development services.
SYNGENE INTERNATIONAL LIMITED
Syngene International Limited is a public company founded in 1993 and headquartered in India. The organization employs 6,692 staff members and provides integrated drug discovery and development services.
LABCORP
LabCorp is a public company founded in 1995 and based in the United States. With 66,385 employees, it operates as a major provider of clinical laboratory and diagnostic services.
EUROFINS SCIENTIFIC
Eurofins Scientific is a public company founded in 1987 and headquartered in Luxembourg. The organization employs 65,694 staff members and provides laboratory testing and analytical services across multiple industries.
Reasons to Buy this Report
- India-Specific Market Sizing : Access precise valuation data for India's PDX market with verified 2025 baseline ($4.1M) and 2030 forecast ($7.0M), enabling accurate business planning and investment decisions specific to the Indian market.
- Growth Trajectory Analysis : Understand India's 11% CAGR performance relative to global 12.5% growth, identifying market dynamics unique to India's oncology research landscape and personalized medicine adoption patterns.
- Investment Opportunity Assessment : Evaluate expansion opportunities in India's emerging PDX research infrastructure, including CRO capabilities, institutional partnerships, and government-backed precision medicine initiatives driving market growth.
- Competitive Positioning Strategy : Develop India-focused strategies by understanding local research institution adoption rates, pharmaceutical company partnerships, and regulatory environment shaping PDX model utilization in the country.
- Regional Market Intelligence : Gain insights into India's role within Asia Pacific PDX markets, identifying how local investments in oncology research and personalized medicine create differentiated opportunities compared to other regional markets.
Frequently asked questions
What is the current market size of PDX Models in India?
India's Patient Derived Xenografts (PDX) Models market is valued at $4.1 million in 2025, with expectations to grow to $7.0 million by 2030.
What is the projected growth rate for India's PDX Models market?
India's PDX Models market is projected to grow at a compound annual growth rate (CAGR) of 11.0% from 2025 to 2030.
Which sectors are driving PDX adoption in India?
India's pharmaceutical companies, research institutions, and biotechnology firms are driving PDX adoption for oncology research and personalized medicine development.
How does India's PDX market compare to the Asia Pacific region?
India represents a significant and growing segment within the Asia Pacific PDX market, with government support and expanding research infrastructure accelerating adoption across the country.
What factors support PDX market growth in India through 2030?
India's PDX market growth is supported by increased oncology research investments, government healthcare innovation initiatives, biotechnology sector expansion, and rising demand for precision medicine platforms.
RESEARCH METHODOLOGY
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global PDX model market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the PDX model market. The secondary sources used for this study include World Health Organization (WHO), American Association for Cancer Research, American Association for Laboratory Animal Science, EurOPDX, European Animal Research Association, European Society for Medical Oncology, European Association for Cancer Research, Federation for Laboratory of Cell Therapy, International Journal of Non-Communicable Diseases, European Medicines Agency (EMA), Alliance for Regenerative Medicine (ARM); ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.
Secondary data were collected and analyzed to determine the overall size of the global PDX model market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the PDX model market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Patient-derived xenografts (PDXs) are models of cancer where the tissue or cells from a patient’s tumor are implanted into an immunodeficient or humanized mouse. These models have been used to grow cancer tissues after they were removed from a patient. The PDX model is an important tool for cancer research. It is used to study the biology of cancer, test the efficacy of new therapies, and predict the response to therapy in individual patients.
The study offers an in-depth analysis of the PDX model market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key PDX model product providers.
Stakeholders
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs)
- Academic & research institutes
- Preclinical and translational research centers
- Life science companies
- Regulatory bodies
- Contract development and manufacturing organizations (CDMOs)
- Cancer research consortia & foundations
- Venture capitalists & strategic investors
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the PDX model market based on implantation method, type, tumor type, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall PDX model market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the PDX model market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as acquisitions, expansions, agreements, partnerships, and collaborations in the PDX model market
- To benchmark players within the PDX model market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Get the Full Patient Derived Xenografts/PDX Models Market Report
Full forecast, segment splits, and company analysis for all Patient Derived Xenografts/PDX Models Market.
- Canada Patient Derived Xenografts/PDX Models Market
- US Patient Derived Xenografts/PDX Models Market
- Germany Patient Derived Xenografts/PDX Models Market
- UK Patient Derived Xenografts/PDX Models Market
- France Patient Derived Xenografts/PDX Models Market
- Italy Patient Derived Xenografts/PDX Models Market
- Spain Patient Derived Xenografts/PDX Models Market
- China Patient Derived Xenografts/PDX Models Market
- Japan Patient Derived Xenografts/PDX Models Market
- Australia Patient Derived Xenografts/PDX Models Market
- South Korea Patient Derived Xenografts/PDX Models Market
- Brazil Patient Derived Xenografts/PDX Models Market
- Mexico Patient Derived Xenografts/PDX Models Market
- UAE Patient Derived Xenografts/PDX Models Market
- Rest Of Europe Patient Derived Xenografts/PDX Models Market
- Rest Of Asia Pacific Patient Derived Xenografts/PDX Models Market
- Rest Of Latin America Patient Derived Xenografts/PDX Models Market
- Kingdom Of Saudi Arabia Patient Derived Xenografts/PDX Models Market
- Rest Of GCC Countries Patient Derived Xenografts/PDX Models Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report